Global trends and hotspots of treatment for nonalcoholic fatty liver disease: A bibliometric and visualization analysis (2010-2023)

Table 2 Top 25 references with strong citations

Rank	Ref.	Year	Primary research content	Strength	Beginning	Ending
1	Sanyal et al[30]	2010	Vitamin E showed improvement in nonalcoholic steatohepatitis in adults without diabetes	161.62	2010	2015
2	Chalasani et al[3]	2018	The diagnosis and management of nonalcoholic fatty liver disease practice guideline	150.14	2013	2017
3	Neuschwander-Tetri et al[31]	2015	Obeticholic acid improved the histological features of nonalcoholic steatohepatitis	102.84	2016	2020
4	Vernon et al[111]	2011	Systematic review: The epidemiology and natural history of NAFDL and NASH in adults	97.78	2012	2016
5	Chalasani et al[2]	2012	A practice guideline of the diagnosis and management of NAFLD	87.88	2013	2017
6	Williams et al[116]	2011	Prevalence of NAFLD was higher than estimated, especially in hispanics and diabetes patients	82.64	2012	2016
7	Promrat et al[35]	2010	Weight reduction achieved through lifestyle intervention led to improvements in liver histology in NASH	80.62	2011	2015
8	Vilar-Gomez et al[11]	2015	NASH resolution/fibrosis regression occurred in patients with ≥ 10% weight loss induced by lifestyle changes	77.63	2016	2020
9	Lavine et al[94]	2011	Neither vitamin E nor metformin was effective in reducing ALT in patients with pediatric NAFLD	76.39	2012	2016
10	Rinella et al[32]	2015	A systematic review of NAFLD	73.68	2016	2020
11	Cohen et al[101]	2011	NAFLD is strongly associated with obesity and insulin resistance	72.23	2012	2016
12	Angulo et al[110]	2015	Fibrosis stage was associated with long-term overall mortality, liver transplantation, and liver-related events	71.71	2016	2020
13	Ratziu et al[22]	2010	Collaboration between hepatologists and specialists in the endocrine, nutritional, and cardiology fields should be encouraged to optimize clinical management	62.53	2011	2015
14	Targher et al[7]	2010	NAFLD was associated with an increased risk of cardiovascular disease	58.16	2011	2015
15	Byrne et al[5]	2015	NAFLD is a multisystem disease, affecting extrahepatic organs and regulatory pathways	57.94	2016	2020
16	Ekstedt et al[108]	2015	Fibrosis stage predicted both overall and disease-specific mortality	57.38	2016	2020
17	Wong et al[109]	2015	NASH has been predicted to become the leading indication for liver transplantation	54.86	2016	2020
18	Anstee et al[112]	2013	NAFLD is associated with liver-related morbidity and mortality and an increased risk of developing cardiovascular disease and T2DM	50.86	2014	2018
19	Younossi et al[53]	2016	As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous	125.36	2018	2021
20	Loomba et al[114]	2013	The epidemiology and demographic characteristics of NAFLD vary worldwide	63.19	2015	2018
21	Tilg et al[115]	2010	Many parallel hits derived from the gut and/or the adipose tissue may promote liver inflammation. endoplasmic reticulum stress and related signaling networks, (adipo) cytokines, and innate immunity are emerging as central pathways that regulate key features of NASH	58.39	2012	2015
22	Buzzetti et al[97]	2016	The multiple-hit pathogenesis of NAFLD	49.79	2018	2021
23	Eslam et al[102]	2020	A diagnosis of MAFLD requires positive criteria	75.68	2021	2023
24	Eslam et al[10]	2020	Renaming NAFLD to MAFLD was proposed to accelerate the translational path to new treatments	68.10	2021	2023
25	Newsome et al[103]	2021	Treatment with semaglutide resulted in a higher percentage of NASH resolution than placebo	55.16	2021	2023

ALT: Alanine aminotransferase; MAFLD: Metabolic dysfunction-associated fatty liver disease; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; T2DM: Type 2 diabetes mellitus.